Home

STEPHEN J HOFFMAN

CIK 1190418 · Chief Executive Officer · last filed 2026-06-24

STEPHEN J HOFFMAN is a Chief Executive Officer who has filed 42 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for TLPH, was dated Jun 24, 2026. Across all open-market trades the lifetime net is +$9.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $18.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$18.1K

Companies

7

Total Filings

42

Lifetime Open-Market Net

$9.40M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TLPH Director 13,959 $1.30 $18.1K $0 3 2026-06-24
TALPHERA, INC. (ACRX) Delisted Director 146,015 $0.86 $125.6K $0 8 2023-12-13
Dicerna Pharmaceuticals Inc (DRNA) Delisted Director 312,000 $38.22 $11.92M $3.00M 9 2021-12-29
Whitehawk Therapeutics, Inc. (ARPO) Delisted Chief Executive Officer 131 $33.00 $4.3K $64.1K 3 2019-05-16
GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Director 249,052 $0.00 $149 $8.79M 4 2016-06-07
ALLOS THERAPEUTICS INC (ALTH) Delisted Director 0 — — -$2.45M 12 2012-09-05
Sirtris Pharmaceuticals, Inc. (SIRT) Delisted Director 1,376,190 — — $0 1 2007-05-31

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-24 TLPH Grant (A) +5,100 $0 EDGAR
2025-10-24 TLPH Grant (A) +4,267 $0 EDGAR
2024-06-24 TLPH Grant (A) +2,174 $0 EDGAR
2023-12-13 TALPHERA, INC. (ACRX) Delisted Grant (A) +581 $0 EDGAR
2022-07-15 TALPHERA, INC. (ACRX) Delisted Grant (A) +15,500 $0 EDGAR
2021-12-29 Dicerna Pharmaceuticals Inc (DRNA) Delisted Mixed −16,157 -$618.0K EDGAR
2021-06-17 TALPHERA, INC. (ACRX) Delisted Grant (A) +10,000 $0 EDGAR
2021-06-07 Dicerna Pharmaceuticals Inc (DRNA) Delisted Mixed +3,333 $0 EDGAR
2020-06-16 Dicerna Pharmaceuticals Inc (DRNA) Delisted Grant (A) — $0 EDGAR
2020-06-16 TALPHERA, INC. (ACRX) Delisted Grant (A) +7,500 $0 EDGAR
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.